Latest News from: Dana-Farber Cancer Institute

Filters close
26-Nov-2019 5:05 PM EST
Treatment with PD-1 inhibitor prior to stem cell transplant is safe, effective for patients with classic Hodgkin lymphoma, study finds
Dana-Farber Cancer Institute

A new analysis shows that a donor stem cell transplant following treatment with an immune checkpoint inhibitor is generally safe and produces good outcomes for patients with Hodgkin lymphoma.

6-Dec-2019 8:30 AM EST
Dana-Farber scientists present promising findings in multiple myeloma at ASH Annual Meeting
Dana-Farber Cancer Institute

Results of studies on a novel agent to treat multiple myeloma and a combination therapy aimed at slowing the progression of a precursor myeloma condition are among reports being presented by Dana-Farber Cancer Institute investigators at the ASH Annual Meeting.

5-Dec-2019 12:05 PM EST
Use of venetoclax in reduced-intensity transplant conditioning regimen in patients with high-risk myeloid cancers shows promise in early trial
Dana-Farber Cancer Institute

For patients with high-risk myeloid cancers undergoing a donor stem cell transplant, adding the targeted drug venetoclax to a reduced-intensity drug regimen prior to transplant is safe and does not impair the ability of the donor cells to take root in recipients’ bodies, a study led by Dana-Farber Cancer Institute researchers suggests.

6-Dec-2019 8:30 AM EST
Genomic features of AML in patients over age 60 can predict success of bone marrow stem cell transplant, research shows
Dana-Farber Cancer Institute

For older patients with acute myeloid leukemia (AML), the prospects for success of a stem cell transplant can often be predicted based on the particular set of genetic mutations within the tumor cells, investigators at Dana-Farber Cancer Institute and other research centers will report today at the ASH Annual Meeting.

Released: 25-Nov-2019 1:25 PM EST
Dana-Farber researchers to present more than 40 studies at 2019 ASH Annual Meeting
Dana-Farber Cancer Institute

Dana-Farber Cancer Institute researchers will present more than 40 research studies at the 61st American Society of Hematology (ASH) Annual Meeting on December 7-10 in Orlando, Fla.

30-Oct-2019 1:05 PM EDT
Study finds racial disparities in culturally competent cancer care
Dana-Farber Cancer Institute

Many non-white minority cancer survivors place importance on seeing doctors who share or understand their culture, but are less likely than non-Hispanic whites to be able to see such physicians, according to a new study from Dana-Farber Cancer Institute and University of Texas Southwestern. The study, which is one of the first nationally-representative studies to examine patient-reported preference for, access to, and quality of provider cultural competency among cancer survivors, published in JAMA Oncology.

Released: 28-Oct-2019 12:15 PM EDT
Dana-Farber Cancer Institute launches new national advertising campaign
Dana-Farber Cancer Institute

Dana-Farber Cancer Institute is launching a new campaign themed, What We Do Here Changes Lives Everywhere”.

Released: 7-Oct-2019 8:55 AM EDT
William G. Kaelin, MD, of Dana-Farber Cancer Institute wins 2019 Nobel Prize
Dana-Farber Cancer Institute

William G. Kaelin Jr., MD, of Dana-Farber Cancer Institute, has been named a winner of the 2019 Nobel Prize in physiology or medicine.

25-Sep-2019 10:05 PM EDT
New blood test capable of detecting multiple types of cancer
Dana-Farber Cancer Institute

A new blood test in development has shown ability to screen for numerous types of cancer with a high degree of accuracy, a trial of the test shows.

Released: 26-Sep-2019 3:30 PM EDT
Dana-Farber Cancer Institute and the Jimmy Fund Debut New Visual Identity
Dana-Farber Cancer Institute

Dana-Farber Cancer Institute unveiled a new visual identity today, modernizing its logo and that of the Jimmy Fund.

Released: 25-Sep-2019 1:05 PM EDT
Resistance to immune checkpoint blocker drug linked to metabolic imbalance
Dana-Farber Cancer Institute

A metabolic imbalance in some cancer patients following treatment with a checkpoint inhibitor drug, nivolumab, is associated with resistance to the immunotherapy agent and shorter survival, report scientists from Dana-Farber Cancer Institute.

12-Sep-2019 3:05 PM EDT
Chronic insomnia can be cured in cancer survivors with a basic, one-session sleep education class, study finds
Dana-Farber Cancer Institute

In a study published online today by the journal Cancer, investigators at Dana-Farber Cancer Institute report that a single-session sleep education program for survivors can cure insomnia in many participants, and that those who don’t benefit from this approach are often helped by a more extensive, but still modest, three-session program.

16-Sep-2019 11:05 AM EDT
Dana-Farber Cancer Institute receives $5 million gift to create the Edward P. Evans Center for Myelodysplastic Syndromes
Dana-Farber Cancer Institute

A $5 million gift from the Edward P. Evans Foundation will create the Edward P. Evans Center for Myelodysplastic Syndromes (MDS) at Dana-Farber Cancer Institute.

Released: 20-Aug-2019 2:45 PM EDT
Dana-Farber Cancer Institute Is Awarded Its Fourth Consecutive Designation as a Magnet® Organization for Excellence in Nursing Practice and Patient Care
Dana-Farber Cancer Institute

Dana-Farber Cancer Institute has been awarded Magnet® status from the American Nurses Credentialing Center (ANCC) for the fourth consecutive time. This prestigious designation recognizes excellence in nursing practice and health care delivery and has been awarded to only 8% percent of hospitals in the United States.

Released: 14-Aug-2019 9:50 AM EDT
Exercise associated with benefit to patients with advanced colorectal cancer
Dana-Farber Cancer Institute

Patients with metastatic colorectal cancer who engaged in moderate exercise while undergoing chemotherapy tended to have delayed progression of their disease and fewer severe side effects from treatment, according to the results of a new study.

12-Aug-2019 8:35 AM EDT
Inherited pancreatic cancer risk mutation identified
Dana-Farber Cancer Institute

The discovery of the previously unknown mutation, reported in Nature Genetics by investigators from Dana-Farber/Brigham and Women’s Cancer Center, could lead to routine testing of individuals with a strong family history of pancreatic cancer to determine if they carry the mutation, occurring in the gene known as RABL3.

23-Jul-2019 11:05 AM EDT
New AI tool developed by Dana-Farber identifies cancer outcomes using radiology reports
Dana-Farber Cancer Institute

Scientists at Dana-Farber Cancer Institute have demonstrated that an artificial intelligence tool can perform as well as human reviewers – and much more rapidly - in extracting clinical information regarding changes in tumors from unstructured radiology reports for patients with lung cancer.

Released: 3-Jul-2019 1:05 PM EDT
Discovery of pancreatic neuroendocrine subtypes could help predict likelihood of recurrence
Dana-Farber Cancer Institute

Researchers have discovered two distinct subtypes of pancreatic neuroendocrine tumors – known as pNETs – that have dramatically different risks of recurrence following surgical treatment [or surgery]. The finding could yield predictive tests, ease anxiety in patients whose tumors are found to be unlikely to recur, while focusing vigilant follow-up monitoring on patients with pNETs having a higher rate of recurrence.

28-Jun-2019 3:00 PM EDT
High doses of 60-plus year-old chemotherapy drug found to spur immune system attack on lymphoma
Dana-Farber Cancer Institute

Cyclophosphamide, a mainstay of chemotherapy for many cancers, acts as both chemotherapy and immunotherapy at high doses, study finds

Released: 5-Jun-2019 4:50 PM EDT
Walking Speed Points to Future Clinical Outcomes for Older Patients with Blood Cancers
Dana-Farber Cancer Institute

Researchers at Dana-Farber Cancer Institute and the VA Boston Healthcare System have uncovered a new vital sign for gauging survival and likelihood of having an unplanned hospitalization in older patients with blood cancers: the speed at which they can walk.In a study published today in the journal Blood, the researchers report that for every 0.

2-Jun-2019 6:30 AM EDT
Enzalutamide improves survival for men with metastatic hormone-sensitive prostate cancer
Dana-Farber Cancer Institute

Enzalutamide, an oral androgen receptor inhibitor, can improve outcomes for men with metastatic hormone-sensitive prostate cancer (mHSPC), according to a large study presented by Christopher Sweeney, MBBS of Dana-Farber Cancer Institute's Lank Center for Genitourinary Oncology, during the American Society of Clinical Oncology (ASCO) Annual Meeting.

30-May-2019 2:05 PM EDT
Pre-surgical immunotherapy shows promise in trial for patients with early stage lung cancer
Dana-Farber Cancer Institute

Pre-surgical immunotherapy shows promise in trial for patients with early stage lung cancer

29-May-2019 12:00 PM EDT
Patterns of chronic lymphocytic leukemia growth identified
Dana-Farber Cancer Institute

In patients with chronic lymphocytic leukemia, the rate of disease growth is apt to follow one of three trajectories: relentlessly upward, steadily level, or something in between, scientists at Dana-Farber Cancer Institute, the Broad Institute of MIT and Harvard, Massachusetts General Hospital, and the University of Washington report in a new study.

21-May-2019 1:05 PM EDT
Black Men Less Likely Than Nonblack Patients to Adopt Active Surveillance for Low-Risk Prostate Cancer
Dana-Farber Cancer Institute

At a time when a growing number of men with prostate cancer considered “low risk” are opting for active surveillance or watchful waiting rather than immediate treatment with surgery or radiation, a new study reveals that black men are less likely than white men to adopt an active surveillance strategy for their disease.

Released: 16-May-2019 3:05 PM EDT
Dana-Farber researchers present findings in more than 70 research studies at ASCO annual meeting 2019
Dana-Farber Cancer Institute

Dana-Farber Cancer Institute researchers are presenting more than 70 research studies at the 2019 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 31st- June 4th. ASCO is the world’s largest clinical cancer research meeting, attracting more than 30,000 oncology professionals from around the world.

23-Apr-2019 11:05 AM EDT
Targeted therapy proves effective against aggressive rare blood cancer
Dana-Farber Cancer Institute

Clinical study treating BPDCN with tagraxofusp led to first FDA approval for the disease

Released: 23-Apr-2019 12:05 PM EDT
Researchers devise a progression risk-based classification for patients with asymptomatic Waldenström macroglobulinemia
Dana-Farber Cancer Institute

Researchers at Dana-Farber Cancer Institute have devised a risk model for determining whether patients with AWM have a low, intermediate, or high risk of developing symptomatic Waldenström macroglobulinemia

8-Apr-2019 12:05 PM EDT
High-dose vitamin D shows benefit in patients with advanced colorectal cancer
Dana-Farber Cancer Institute

Results of a small clinical trial suggest that supplementing chemotherapy with high doses of vitamin D may benefit patients with metastatic colorectal cancer by delaying progression of the disease, say scientists from Dana-Farber Cancer Institute.

Released: 27-Mar-2019 1:30 PM EDT
T-Mobile CEO John Legere delivers $4.5 million gift to Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

T-Mobile CEO is giving $4.5 million to support the Profile initiative at Dana-Farber Cancer Institute, one of the broadest and most comprehensive enterprise-level, patient-based cancer genomics projects in the world.

15-Mar-2019 11:05 AM EDT
Adult cells maintain a virtually complete molecular “memory” of their embryonic origins, researchers find
Dana-Farber Cancer Institute

• Study uncovers extensive archive within adult cells of genes active at embryonic stage • Memory can be accessed under certain conditions, making it possible to reactivate fetal genes • Discovery may have major implications for regenerative medicine, cancer research

Released: 15-Mar-2019 9:00 AM EDT
Cigall Kadoch, PhD, chosen for 2019 Wachtel Cancer Research Prize
Dana-Farber Cancer Institute

Dana-Farber researcher Cigall Kadoch, PhD, named recipient of Wachtel Cancer Research Prize

13-Mar-2019 6:05 PM EDT
New study on Serious Illness Care Program underscores significant benefit of more, better, and earlier conversations between clinicians and patients
Dana-Farber Cancer Institute

A new study shows that an innovative communication program developed by Ariadne Labs and tested at the Dana-Farber Cancer Institute resulted in more, earlier and better conversations between patients and their oncology clinicians, and led to significant reductions in emotional suffering for patients with advanced cancer.

Released: 5-Mar-2019 9:40 AM EST
New center addresses alarming increase in colorectal cancer rates among young adults
Dana-Farber Cancer Institute

Dana-Farber/Brigham and Women's Cancer Center announced the launch of the Young-Onset Colorectal Cancer Center. The center will provide expert, compassionate and cutting-edge care to young adult colon and rectal cancer patients with a focus on scientific discovery and research.

Released: 4-Mar-2019 8:30 AM EST
Dana-Farber Opens Center for the Prevention of Progression Clinic
Dana-Farber Cancer Institute

Dana-Farber Cancer Institute opens Center for the Prevention of Progression clinic to focus on precursor conditions in blood cancers

15-Feb-2019 2:05 PM EST
Drug combination may become new standard treatment for advanced kidney cancer
Dana-Farber Cancer Institute

A combination of two drugs – one of them an immunotherapy agent – could become a new standard, first-line treatment for patients with metastatic kidney cancer, says an investigator from Dana-Farber Cancer Institute, reporting results from a phase 3 clinical trial.

11-Feb-2019 8:55 AM EST
Study Finds Upsurge in ‘Active Surveillance’ for Low-Risk Prostate Cancer
Dana-Farber Cancer Institute

Many men with low-risk prostate cancer who most likely previously would have undergone immediate surgery or radiation are now adopting a more conservative “active surveillance” strategy, according to an analysis of a new federal database by scientists from Dana-Farber Cancer Institute.

Released: 7-Jan-2019 9:45 AM EST
Personalized vaccine to be tested for the first time in patients with kidney cancer
Dana-Farber Cancer Institute

By pairing a novel personalized cancer vaccine with a more established immunotherapy drug that is administered to patients in an innovative fashion, scientists at Dana-Farber Cancer Institute are testing a first-of-its-kind strategy aimed at improving outcomes for kidney cancer patients who are at high risk of recurrence following surgery.

19-Dec-2018 11:00 AM EST
Neoantigen vaccine spurs immune response in glioblastoma
Dana-Farber Cancer Institute

In a report published in Nature, however, scientists at Dana-Farber Cancer Institute say they have shown that a personalized ‘neoantigen’ vaccine can spur a response against glioblastoma, with immune T-cells generated by the vaccine migrating into the brain tumor, creating a ‘hotter,’ inflamed environment around the cancer cells.

Released: 18-Dec-2018 1:00 PM EST
James Terwilliger named as Executive Vice President and Chief Operating Officer at Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

New Executive Vice President and Chief Operating Officer named at Dana-Farber Cancer Institute

17-Dec-2018 2:05 PM EST
Prostate cancer scoring method may underestimate mortality risk in black men
Dana-Farber Cancer Institute

Black men diagnosed with prostate cancer classified as low risk may actually have a more aggressive form of the disease that is more likely to be fatal than in nonblack men placed in the same prognostic category, a new study suggests.

3-Dec-2018 10:30 AM EST
Dana-Farber Scientists to Present Research on Myeloma Progression From Precursor Conditions and Novel Approaches to Treatment
Dana-Farber Cancer Institute

Dana-Farber Cancer Institute scientists will present research marking significant advances against the hematologic cancer multiple myeloma at the ASH Annual Meeting.

3-Dec-2018 6:30 PM EST
Dana-Farber Scientists to Present New Research on Improving Outcomes in Stem Cell Transplantation for Myeloid Cancers
Dana-Farber Cancer Institute

Improving outcomes for patients with myeloid cancers who undergo stem cell transplantation is a focus of several studies to be presented by Dana-Farber Cancer Institute scientists at the ASH Annual Meeting.

2-Dec-2018 12:30 PM EST
Dana-Farber Researchers Report Clinical Trial Results in Treatment of Leukemia and Lymphoma
Dana-Farber Cancer Institute

New results from clinical trials of immunotherapy and experimental targeted agents for patients with leukemia and lymphoma are being presented by Dana-Farber Cancer Institute researchers at the ASH Annual Meeting.

Released: 29-Nov-2018 9:00 AM EST
Venetoclax Combination Approved for Elderly AML
Dana-Farber Cancer Institute

A new option – a combination of a standard drug and the novel agent venetoclax – has been granted accelerated approval by the Food and Drug Administration for certain AML patients after a large, multicenter phase 1 clinical trial showed the combination had “promising efficacy” and was well tolerated in older AML patients.

20-Nov-2018 10:05 AM EST
Pancreatic Cancer Collective awards Dana-Farber Cancer Institute researchers “New Therapies Challenge” grant
Dana-Farber Cancer Institute

• $1 million in initial funding to evaluate DNA repair inhibitors in pancreatic cancer • Aim to accelerate pancreatic cancer research and improve patient outcomes for pancreatic cancer

Released: 13-Nov-2018 8:05 AM EST
Dana-Farber Cancer Institute and Deerfield Collaborate to Create the Center for Protein Degradation
Dana-Farber Cancer Institute

Dana-Farber and Deerfield Management are collaborating to create the Center for Protein Degradation is to interrogate and advance a large portfolio of advanced targeted protein degrader targets while creating a next-generation protein degrader platform

Released: 5-Nov-2018 3:05 PM EST
Dana-Farber Scientists Find New Drug Targets in Aggressive Cancers
Dana-Farber Cancer Institute

Scientists have discovered a previously unknown molecular vulnerability in two rare, aggressive, and hard-to-treat types of cancer, and say it may be possible to attack this weakness with targeted drugs.

Released: 30-Oct-2018 2:45 PM EDT
Study Uncovers Key Parts of Mechanism for Activating T Cells to Fight Cancer and Other Diseases
Dana-Farber Cancer Institute

In a study published online today by the journal Immunity, scientists at Dana-Farber Cancer Institute, Harvard Medical School, Vanderbilt University and colleagues at other institutions show how machinery within immune system T cells responds to outside signals and activates the cells to attack cancerous, infected, or otherwise diseased cells.

Released: 5-Oct-2018 2:05 PM EDT
Teams from Dana-Farber and Boston Children’s Hospital win Moonshot grants to probe childhood cancers
Dana-Farber Cancer Institute

In an ambitious effort to crack the code of several aggressive childhood cancers that lack definitive treatments, the federal Beau Biden Cancer Moonshot program has awarded grants of $2.5 million each over five years to two research teams led by scientists from Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. Only three grants in total were awarded for this initiative.

   
Released: 2-Aug-2018 10:00 AM EDT
Dana-Farber Launches Chinese-Language Website
Dana-Farber Cancer Institute

Dana-Farber Cancer Institute launches a new Chinese-language website.



close
1.54388